Lotus Pharmaceutical Announces Licensing and Commercialization Agreement with Alvotech for Biosimilar Candidates to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets

Taipei, Taiwan, 21 August 2026 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, today announced a strategic licensing and commercialization agreement with Alvotech (NASDAQ: ALVO) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to Hemlibra® (emicizumab).

Imfinzi® is an oncology biologic used in the treatment of multiple cancers, which generated global sales of approximately USD6.1 billion in 2025¹. Hemlibra® is a biologic for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A that generated global sales of approximately CHF4.8 billion in 2025, equivalent to approximately USD5.8 billion².

In the United States, Lotus will commercialize both products under a semi-exclusive arrangement with Alvotech, which will retain the right to commercialize the products directly. Alvotech will retain responsibility for product development and for obtaining and maintaining marketing authorizations in the United States, and will serve as the exclusive supplier of the products across all markets covered by the agreement.

In Asia, Lotus will have exclusive commercialization rights in eight selected markets: South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia. Lotus will be responsible for local regulatory submissions and commercialization in these markets.

Petar Vazharov, Chief Executive Officer of Lotus, commented, “We are pleased to partner with Alvotech on two important biosimilar candidates that meaningfully advance Lotus’ global growth strategy. By combining Alvotech’s integrated biosimilar development and manufacturing capabilities with Lotus’ established commercial platform and market presence in the US and Asia, we are building a strong foundation for the future commercialization of AVT34 and AVT87 across key global markets. These candidates expand the scale and reach of our biosimilar portfolio in oncology and rare diseases, and reinforce our commitment to broadening access to high-quality medicines.”

Imfinzi® and Hemlibra® are registered trademarks and the property of their respective owners.

1)             AstraZeneca PLC. (2026). Annual report on Form 20-F for the fiscal year ended December 31, 2025. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm

 

2)            Roche, Finance Report 2025, F. Hoffmann-La Roche Ltd, based on FX rate of 1 CHF = 1.21 USD  https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf

 

 

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.